Versant Venture Capital IV, L.P., Director at CRISPR Therapeutics AG (CRSP), sold 14,514 shares at $49.63 ($720K) on 2026-10-14, disclosed to the SEC on 2026-10-16.
Scheduled sale ($720k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| CRSP | BUY | 2016-12-23 | $2.3M | — | Filing → |